<DOC>
	<DOCNO>NCT01613300</DOCNO>
	<brief_summary>The aim study rate acute graft-versus-host disease II-IV measure day +365according conventional criterion ( Przepiorka et al . 1995 ) patient high risk non-Hodgkin lymphoma B subject Allogeneic Stem Cell Transplant</brief_summary>
	<brief_title>Study OFATUMUMAB Part Scheme Reduced Intensity Conditioning High Risk Non-Hodgkin Lymphoma B Patients</brief_title>
	<detailed_description>In addition : - Rate progression-free survival ( PFS ) 12 , 24 , 36 60 month post-transplant defined time infusion progenitor disease progression death . Patients alive complete remission censor time last follow - Transplant-related mortality ( TRM ) 12 , 24 , 36 60 month transplantation , define death cause directly lymphoma ( death cause complication related transplantation ) . - Overall survival ( OS ) define time infusion progenitor patient 's death cause . Alive Patients censor time last follow-up - Incidence chronic graft versus host disease ( GVHD ) wide 1 5 year accord conventional criterion ( Atkinson et al . 1989 ) Filipovich et al . ( BBMT , 2005 ) . - Rate event-free survival ( DFS ) define time interval diagnosis lymphoma lymphoma progression relapse death occur . - Successful graft implantation : define : 1. º : three consecutive day absolute neutrophil count great 0.5 * 109 / L 2 . ° thrombocythemia exceeds 20 * 109 / L. - Reconstitution immune system : lymphocyte count population CD20 , CD3 , CD4 CD8 immunoglobulinemia serum ( day +100 , 180 , 360 , 18 month 24 month ) . - intercurrent infection . All sort infection ( viral , fungal bacterial ) record - Safety assessment standard Common Terminology Criteria adverse event v. 4.0</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects give informed consent studyspecific procedures 2 . Histopathological diagnostic NHL cell B CD 20 + B different histologic subtypes : 3 . High risk CD +20 Lymphoma least one follow characteristic : Less partial remission two course treatment Relapse autologous peripheral blood stem cell ( PBSCT ) Evidence measurable disease ( With CT PET PET / CT ) three month PBSCT Hematopoietic precursor improper count patient relapse partial remission two treatment line prevent realization PBSCT . Patients first relapse RP two line treatment probability freedom progression per year low due risk factor : first CR le 12 month PBSCT low SLP , etc.. 4 . Age 18 65 year 5 . ECOG 0 1 ( Appendix III ) . 6 . Subjects HBgAG negative , antiHBc positive HBV DNA negative may include study must undergo HBV DNA monitor 7 . Adequate lung Function 8 . Cardiac ejection great 40 % measure scintigraphy echocardiography . 9 . Adequate renal hepatic function define follow biochemical parameter 10 . The disease status prior transplantation place accordance criterion Revised Response Criteria Malignant Lymphoma , Cheson 2007 . CT PET PET / CT. 11 . Availability histocompatible donor ( 9 10/10 locus ) family unrelated 12 . Adults ability procreate must commit use effective method birth control study treatment least 6 month . 1 . Refractory disease time transplantation 2 . Progressive disease time transplantation . 3 . ECOG≤2 4 . Lymphoma associated infection human immunodeficiency virus ( HIV ) . 5 . Test positive HIV . 6 . Presence antimurine antibody ( HAMA ) ( HACA ) . 7 . Treatment market experimental drug administer period 5 terminal halflives clearance therapy 4 week enrollment 8 . Participation another interventional clinical trial . 9 . Prior treatment antiCD20 monoclonal antibody alemtuzumab within 3 month prior start therapy . This generally require may exclude applicable . 10 . Hepatitis B positive serology 11 . Positive serology Hepatitis B ( HB ) define positive test HBsAg . 12 . Positive serology hepatitis C ( HC ) define positive test HCAb . 13 . Active liver biliary disease ( exception Gilbert 's disease , cholelithiasis , metastasis ) . 14 . Other past current malignancy . 15 . Chronic infectious disease require ongoing treatment systemic antibiotic , antifungal antiviral drug 16 . History cerebrovascular disease active last 6 month event significant symptom sequela . 17 . Clinically significant heart disease , unstable angina , acute myocardial infarction six month prior inclusion , congestive heart failure ( grade IIIIV NYHA ) arrhythmia unless control treatment , except premature disorder Mild drive . 18 . Concurrent medical disorder , uncontrolled important , kidney disease , liver , digestive , endocrine , pulmonary , neurological , brain , psychiatric , opinion investigator may represent risk patient 19 . Pregnancy breastfeed 20 . Women childbearing potential , include whose last menstrual period one year prior screen . 21 . Men unable unwilling use contraception 22 . Patients hypersensitivity fludarabine , melphalan , thiotepa , tacrolimus , sirolimus / excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hodgkin</keyword>
	<keyword>disease</keyword>
	<keyword>ofatumumab</keyword>
</DOC>